市場調査レポート

商品コード

1414722

HIV治療薬市場：薬剤クラス別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年11月30日 | 発行: Allied Market Research

| ページ情報: 英文 35 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,820 912,343円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,540 1,025,210円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,870 1,547,221円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

HIV治療薬市場は、2022年には328億米ドルと評価され、2023年から2032年までのCAGRは4.5%で成長し、2032年には511億米ドルに達すると推定されています。

ヒト免疫不全ウイルス（HIV）は、身体の免疫系を攻撃する感染症の一種です。身体を弱らせ、あらゆる病気にかかりやすくします。HIVの治療には、ヌクレオシド系逆転写酵素阻害薬（NRTI）、プロテアーゼ阻害薬（PI）、エントリー阻害薬、HIVインテグラーゼ鎖移行阻害薬などの抗レトロウイルス薬（HIV治療薬）が使用されます。

本レポートのカスタマイズが可能です（別途費用とスケジュールが必要です。）

市場戦略
製品/セグメント別企業の市場セグメンテーション
主要企業の新製品開発/製品マトリックス
クライアントの関心に応じた追加企業プロファイル
平均販売価格分析／プライスポイント分析
ブランドシェア分析
クリスクロスセグメント分析-市場規模と予測
過去の市場データ
主要プレーヤーの詳細（所在地、連絡先、サプライヤー／ベンダーネットワークなどを含む、エクセル形式）
SWOT分析

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - HIV感染者の増加
  - HIV/AIDSの診断と管理に関する認識を高めるための様々な政府団体による取り組み
  - HIV治療薬のジェネリック医薬品のイントロダクション
- 抑制要因
  - HIV治療薬の承認と商業化のための厳しい規制要件
- 機会
  - パイプライン製品の増加

第4章 HIV治療薬市場：薬剤クラス別

概要
薬剤クラス別併用薬
- 薬剤クラス別配合剤HIV治療薬のブランド別市場
ヌクレオシド逆転写酵素阻害薬（NRTI）
- ヌクレオシド系逆転写酵素阻害薬（NRTI）ブランド別HIV治療薬市場
非ヌクレオシド系逆転写酵素阻害薬（NNRTI）
- 非ヌクレオシド系逆転写酵素阻害薬（NNRTI）HIV治療薬のブランド別市場
プロテアーゼ阻害薬（PI）
- プロテアーゼ阻害剤（PI）HIV治療薬のブランド別市場
エントリー阻害剤
- エントリー阻害剤のブランド別HIV治療薬市場
HIVインテグラーゼ鎖移行阻害薬
- HIVインテグラーゼ鎖移行阻害薬HIV治療薬のブランド別市場
その他

第5章 HIV治療薬市場：流通チャネル別

概要
病院薬局
ドラッグストアおよび小売薬局
オンライン薬局

第6章 HIV治療薬市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他

第7章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第8章企業プロファイル

AbbVie Inc.
Merck & Co., Inc.
Boehringer Ingelheim International GmbH
Gilead Sciences, Inc.
GlaxoSmithKline plc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Cipla Ltd.
Bristol-Myers Squibb Company

図表

LIST OF TABLES

TABLE 01. GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 02. HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL MULTI-CLASS COMBINATION DRUGS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 04. HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 06. HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 08. HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL PROTEASE INHIBITORS (PIS) HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 10. HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL ENTRY INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 12. HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL HIV INTEGRASE STRAND TRANSFER INHIBITORS HIV DRUGS MARKET, BY BRAND, 2022-2032 ($MILLION)
TABLE 14. HIV DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 18. HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 19. HIV DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 23. U.S. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 24. U.S. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. CANADA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 26. CANADA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 27. MEXICO HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 28. MEXICO HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 30. EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 33. GERMANY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. FRANCE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 35. FRANCE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. UK HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 37. UK HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. ITALY HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 39. ITALY HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. SPAIN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 41. SPAIN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. REST OF EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 43. REST OF EUROPE HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 45. ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 46. ASIA-PACIFIC HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 47. JAPAN HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 48. JAPAN HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. CHINA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 50. CHINA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. AUSTRALIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 52. AUSTRALIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. INDIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 54. INDIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. SOUTH KOREA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 56. SOUTH KOREA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 58. REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 60. LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. LAMEA HIV DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 62. BRAZIL HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 63. BRAZIL HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SAUDI ARABIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 65. SAUDI ARABIA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. SOUTH AFRICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 67. SOUTH AFRICA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 68. REST OF LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2022-2032 ($MILLION)
TABLE 69. REST OF LAMEA HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. ABBVIE INC.: KEY EXECUTIVES
TABLE 71. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 72. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 73. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 74. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 75. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 76. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 77. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 78. MERCK & CO., INC.: KEY STRATERGIES
TABLE 79. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
TABLE 80. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 81. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT SEGMENTS
TABLE 82. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 83. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 84. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 85. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 86. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 87. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 88. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 89. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 90. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 91. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 92. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 93. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 94. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 95. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 96. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 97. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 99. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 100. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 106. CIPLA LTD.: KEY EXECUTIVES
TABLE 107. CIPLA LTD.: COMPANY SNAPSHOT
TABLE 108. CIPLA LTD.: PRODUCT SEGMENTS
TABLE 109. CIPLA LTD.: PRODUCT PORTFOLIO
TABLE 110. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 111. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. HIV DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF HIV DRUGS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN HIV DRUGS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN HIV DRUGS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL HIV DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. HIV DRUGS MARKET, BY MEDICATION CLASS, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR MULTI-CLASS COMBINATION DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS), BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR PROTEASE INHIBITORS (PIS), BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ENTRY INHIBITORS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF HIV DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. HIV DRUGS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 24. U.S. HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. JAPAN HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. CHINA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. INDIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF ASIA-PACIFIC HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. BRAZIL HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SAUDI ARABIA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF LAMEA HIV DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44. COMPETITIVE DASHBOARD
FIGURE 45. COMPETITIVE HEATMAP: HIV DRUGS MARKET
FIGURE 46. TOP PLAYER POSITIONING, 2022
FIGURE 47. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 48. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 49. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 51. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 64. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. CIPLA LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 68. CIPLA LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. CIPLA LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 70. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A01537

According to a new report published by Allied Market Research, titled, "HIV Drugs Market," The hiv drugs market was valued at $32.8 billion in 2022, and is estimated to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032. Human immunodeficiency virus (HIV) is a type of infection that attacks the immune system of the body. It weakens the body and makes it easier to get sick with any diseases. The antiretroviral drugs (HIV drugs) such as nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), entry inhibitors, HIV integrase strand transfer inhibitors and others are used for the treatment of HIV.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Go To Market Strategy
Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Average Selling Price Analysis / Price Point Analysis
Brands Share Analysis
Criss-cross segment analysis- market size and forecast
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Medication Class

Multi-Class Combination Drugs
- Brand
- Atripla
- Complera
- Prezcobix
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Dovato
- Others
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Brand
- Emtriva
- Epivir
- Epzicom/Kivexa
- Truvada
- Biktarvy
- Others
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Brand
- Edurant
- Others
Protease Inhibitors (PIs)
- Brand
- Aptivus
- Kaletra
- Lexiva/ Telzir
- Norvir
- Viracept
- Others
Entry Inhibitors
- Brand
- Selzentry
- Fuzeon
- Rukobia
HIV Integrase Strand Transfer Inhibitors
- Brand
- Isentress/Isentress HD
- Tivicay
- Apretude
- Juluca
Others

By Distribution Channel

Hospital Pharmacies
Drugs stores and retail pharmacies
Online pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Merck & Co., Inc.
Cipla Ltd.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
GlaxoSmithKline plc
Johnson & Johnson

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in cases of HIV
  - 3.4.1.2. Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
  - 3.4.1.3. Introduction of generic drugs for HIV
- 3.4.2. Restraints
  - 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
- 3.4.3. Opportunities
  - 3.4.3.1. Increasing number of products in the pipeline

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Multi-Class Combination Drugs
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Multi-Class Combination Drugs HIV Drugs Market by Brand
4.3. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) HIV Drugs Market by Brand
4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.4.4. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) HIV Drugs Market by Brand
4.5. Protease Inhibitors (PIs)
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.5.4. Protease Inhibitors (PIs) HIV Drugs Market by Brand
4.6. Entry Inhibitors
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- 4.6.4. Entry Inhibitors HIV Drugs Market by Brand
4.7. HIV Integrase Strand Transfer Inhibitors
- 4.7.1. Key market trends, growth factors and opportunities
- 4.7.2. Market size and forecast, by region
- 4.7.3. Market share analysis by country
- 4.7.4. HIV Integrase Strand Transfer Inhibitors HIV Drugs Market by Brand
4.8. Others
- 4.8.1. Key market trends, growth factors and opportunities
- 4.8.2. Market size and forecast, by region
- 4.8.3. Market share analysis by country

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Hospital Pharmacies
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drugs stores and retail pharmacies
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Online pharmacies
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: HIV DRUGS MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Medication Class
- 6.2.3. Market size and forecast, by Distribution Channel
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Medication Class
  - 6.2.4.1.2. Market size and forecast, by Distribution Channel
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Medication Class
  - 6.2.4.2.2. Market size and forecast, by Distribution Channel
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Medication Class
  - 6.2.4.3.2. Market size and forecast, by Distribution Channel
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Medication Class
- 6.3.3. Market size and forecast, by Distribution Channel
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Medication Class
  - 6.3.4.1.2. Market size and forecast, by Distribution Channel
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Medication Class
  - 6.3.4.2.2. Market size and forecast, by Distribution Channel
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Medication Class
  - 6.3.4.3.2. Market size and forecast, by Distribution Channel
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Medication Class
  - 6.3.4.4.2. Market size and forecast, by Distribution Channel
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Medication Class
  - 6.3.4.5.2. Market size and forecast, by Distribution Channel
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Medication Class
  - 6.3.4.6.2. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Medication Class
- 6.4.3. Market size and forecast, by Distribution Channel
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Market size and forecast, by Medication Class
  - 6.4.4.1.2. Market size and forecast, by Distribution Channel
  - 6.4.4.2. China
  - 6.4.4.2.1. Market size and forecast, by Medication Class
  - 6.4.4.2.2. Market size and forecast, by Distribution Channel
  - 6.4.4.3. Australia
  - 6.4.4.3.1. Market size and forecast, by Medication Class
  - 6.4.4.3.2. Market size and forecast, by Distribution Channel
  - 6.4.4.4. India
  - 6.4.4.4.1. Market size and forecast, by Medication Class
  - 6.4.4.4.2. Market size and forecast, by Distribution Channel
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Medication Class
  - 6.4.4.5.2. Market size and forecast, by Distribution Channel
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Medication Class
  - 6.4.4.6.2. Market size and forecast, by Distribution Channel
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Medication Class
- 6.5.3. Market size and forecast, by Distribution Channel
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Medication Class
  - 6.5.4.1.2. Market size and forecast, by Distribution Channel
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Market size and forecast, by Medication Class
  - 6.5.4.2.2. Market size and forecast, by Distribution Channel
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Market size and forecast, by Medication Class
  - 6.5.4.3.2. Market size and forecast, by Distribution Channel
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Market size and forecast, by Medication Class
  - 6.5.4.4.2. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. Merck & Co., Inc.
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. Boehringer Ingelheim International GmbH
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Gilead Sciences, Inc.
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
- 8.4.7. Key strategic moves and developments
8.5. GlaxoSmithKline plc
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
8.6. Johnson & Johnson
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. F. Hoffmann-La Roche Ltd.
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Teva Pharmaceutical Industries Ltd.
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
8.9. Cipla Ltd.
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
8.10. Bristol-Myers Squibb Company
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Business performance

HIV治療薬市場：薬剤クラス別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章 HIV治療薬市場：薬剤クラス別

第5章 HIV治療薬市場：流通チャネル別

第6章 HIV治療薬市場：地域別

第7章競合情勢

第8章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By Medication Class

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 6: HIV DRUGS MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

HIV治療薬市場：薬剤クラス別、流通チャネル別：世界の機会分析と産業予測、2023年～2032年

HIV Drugs Market By Medication Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 HIV治療薬市場：薬剤クラス別

第5章 HIV治療薬市場：流通チャネル別

第6章 HIV治療薬市場：地域別

第7章 競合情勢

第8章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

By Medication Class

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: HIV DRUGS MARKET, BY MEDICATION CLASS

CHAPTER 5: HIV DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 6: HIV DRUGS MARKET, BY REGION

CHAPTER 7: COMPETITIVE LANDSCAPE

CHAPTER 8: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第7章競合情勢

第8章企業プロファイル